Pemphigus

Published on 19/03/2015 by admin

Filed under Dermatology

Last modified 19/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1549 times

Pemphigus

Daniel Mimouni and Grant J. Anhalt

Evidence Levels:  A Double-blind study  B Clinical trial ≥ 20 subjects  C Clinical trial < 20 subjects  D Series ≥ 5 subjects  E Anecdotal case reports

image

Pemphigus is an autoimmune blistering disease of the skin with an established immunological basis but unknown etiology. Its histological hallmark is the loss of cell-to-cell adhesion (acantholysis) mediated by autoantibodies to epidermal cell-surface proteins. Pemphigus has three major variants, pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus, which are differentiated by the presence/absence of intraepithelial blisters and erosions of the skin and variable involvement of the mucous membranes. Their associated risks of morbidity and mortality vary greatly.

Management strategy

If pemphigus vulgaris is not treated definitively and promptly, the process ‘hardens’, leading to epitope spreading which makes the disease more difficult to control. Even if the initial presentation is limited, without systemic treatment it will generalize. Animal studies have clearly shown that once enough autoantibody reaches the skin, blistering will occur, and this damage cannot be prevented by anti-inflammatory agents or even pretreatment with high doses of systemic corticosteroids. Topical treatment of the mucous membranes or skin has no significant effect on the course of the disease, though topical corticosteroids or intralesional injections or corticosteroids may temporarily relieve pain and inflammation.

Other factors complicate the management, and include the following:

1. Circulating autoantibodies have a degradative half-life of about 3 weeks. Lasting improvement can only occur with reduction of both existing and newly produced antibody, so improvement occurs very slowly unless the antibodies are physically removed by plasmapheresis, or their catabolism is increased by administration of high doses of exogenous normal human immunoglobulins (IVIG).

2. Pemphigus is notorious in its persistence. Spontaneous remissions typically do not occur, and remissions and relapses are common. Most people require some form of treatment for life.

3. There is only a small repertoire of drugs that are effective at reducing autoantibody synthesis, and the most effective of those are rituximab and cyclophosphamide. The high cost of rituximab can be a barrier to treatment and cyclophosphamide has potential toxicities that cause concern to many treating physicians and can restrict the appropriate use of this drug.

4. All forms of pemphigus are rare, and this prohibits the execution of large, controlled trials. The literature discussing therapeutic regimens is dominated by small series and case reports, which is a weak evidence base for the design of rational treatment. However, we do have excellent animal models of this disease, and understand well the pathophysiology from these studies, which are instrumental in designing our approach to treatment.

Thus, the primary goal of treatment in all forms of pemphigus is to reduce the synthesis of autoantibodies by the immune system. It currently consists of three basic steps:

The commitment to the use of cyclophosphamide is a serious one. This drug is extremely effective, but use of this alkylating agent is accompanied by short-term leukopenia and a long-term increased risk of leukemia, lymphoma, and bladder cancer, as well as the risk of sterility in younger patients. The increasing use of rituximab is being explored as a way to avert having to use cyclophosphamide.

As mentioned, all types of pemphigus are rare, making large controlled trials difficult to perform. The medical literature on therapeutic regimens is dominated by small series and case reports, which provide a weak evidence base for the design of rational treatment. Some studies have suggested other potential drugs, but they cannot yet be applied because the mechanism whereby they might effectively inhibit new antibody synthesis is unknown. This list includes tetracycline and niacin (nicotinamide), methotrexate, dapsone, and gold. A recent well-performed randomized trial showed no corticosteroid-sparing benefit of cyclosporine. It is therefore not recommended for the treatment of pemphigus vulgaris, although it may still play a role in the treatment of paraneoplastic pemphigus.

Specific investigations

Accuracy of indirect immunofluorescence testing in the diagnosis of paraneoplastic pemphigus.

Helou J, Allbritton J, Anhalt GJ. J Am Acad Dermatol 1995; 32: 441–7.

The diagnosis of pemphigus is established by the fulfillment of three criteria; if one is missing, the diagnosis is uncertain:

Demonstration of IgG autoantibodies on the cell surface of affected epithelium or detection of antigen-specific autoantibodies in the blood. Pemphigus vulgaris is characterized by progressively evolving fragile blisters and erosions. Oral involvement essentially ‘always’ occurs and is the major point to differentiate pemphigus vulgaris from pemphigus foliaceus. Histologic changes include suprabasilar acantholysis and cell surface-bound IgG. Circulating autoantibodies are specific for desmoglein 3 alone when lesions are restricted to the mouth and for both desmogleins 3 and 1 when cutaneous lesions are present in addition to oral lesions. Definition of the specificity of desmoglein autoantibodies can be reliably gained by enzyme-linked immunosorbent assay (ELISA).

In pemphigus foliaceus, mucosal lesions ‘never’ occur. This is the major clinical feature differentiating pemphigus foliaceus from pemphigus vulgaris. The cutaneous lesions are superficial scaling erosions. Immunopathologic studies reveal subcorneal acantholysis and tissue-bound and circulating antidesmoglein 1 antibodies.

Paraneoplastic pemphigus occurs in the context of the several lymphoproliferative disorders: non-Hodgkin lymphoma, chronic lymphocytic leukemia, Castleman disease, thymoma, and retroperitoneal sarcoma. Intractable mucositis with lichenoid erosions is the most constant clinical finding. Polymorphous cutaneous involvement with lesions that resemble erythema multiforme, pemphigus, pemphigoid, or lichenoid eruptions is observed. Histologic study shows suprabasilar acantholysis or interface/lichenoid changes. The key diagnostic finding is the presence of antibodies against desmogleins 3 and 1 and additional autoantibodies against epithelial plakin proteins, such as desmoplakin, envoplakin, and periplakin, which may be identified by immunoblotting or immunoprecipitation techniques. They may also be inferred with immunofluorescence techniques showing their reactivity with murine bladder epithelium, although the lichenoid variant of paraneoplastic pemphigus has been occasionally reported with the complete absence of the characteristic autoantibodies.

First-line therapies

Pemphigus vulgaris and foliaceus
imageSystemic corticosteroids B
imageRituximab D

image

Buy Membership for Dermatology Category to continue reading. Learn more here

Related posts:

Xanthomas Mastocytoses Sporotrichosis Discoid lupus erythematosus Bites and stings Panniculitis